SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
PP&E Net
SCI Pharmtech Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
PP&E Net
NT$4.8B
|
CAGR 3-Years
32%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
PP&E Net
NT$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
PP&E Net
NT$6.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
PP&E Net
NT$4.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
PP&E Net
NT$3.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
PP&E Net
NT$4.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's PP&E Net?
PP&E Net
4.8B
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's PP&E Net amounts to 4.8B TWD.
What is SCI Pharmtech Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
10%
Over the last year, the PP&E Net growth was 23%. The average annual PP&E Net growth rates for SCI Pharmtech Inc have been 32% over the past three years , 21% over the past five years , and 10% over the past ten years .